# Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

- Source: PR Newswire
- Published: 2026-10-25T07:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-reports-75-tumor-response-rate-in-advanced-prostate-cancer-with-jnj-6143-a-first-in-class-riptac-molecule-302918733.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-reports-75-tumor-response-rate-in-advanced-prostate-ca-9aa7fe/

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cells Among patients with measurable disease in...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._